Darling Ingredients (DAR) is drawing notable analyst attention this quarter, with nine major firms — including Scotiabank, UBS, JPMorgan (JPM), BofA, Jefferies, TD Cowen, BMO Capital, Piper Sandler, and Baird — all raising their price targets on the stock. At the same time, Capital One (COF) has seen a fair value estimate reduction of $11.76 per share, as the company's $5.15 billion Brex acquisition remains a key strategic focus. Though both stocks sit at the heart of analyst revisions, the stories driving their direction diverge in important ways ahead of next week's session.
Darling Ingredients: Broad Analyst Target Lifts Signal Shifting Valuations
The latest target revisions for Darling Ingredients (DAR) include a fair value estimate moving from $64.08 to $68.33. Individual analyst target hikes span from $2 at the low end to $20 at the high end, per summaries from Simply Wall St. Scotiabank increased its target to $61 from $45 while maintaining its Outperform rating, according to published notes. Jefferies has highlighted the final EPA Renewable Fuel Standard (RFS) volume mandates as a particular positive and grouped DAR with ADM as key beneficiaries. Notably, Baird has backed up its early-February upgrade with a further refreshed target, according to the analyst roundup.
Stocks365 Take: The cluster of upward target revisions is substantial, but most houses are raising price targets rather than shifting their core ratings. This signals growing optimism within current frameworks, but not the type of full-scale upgrade wave that typically precedes a major rerating. Jefferies' emphasis on policy-driven tailwinds over purely operational momentum sets up regulatory events—especially related to the RFS—as critical to how the stock trades from here. If new details emerge soon, the range between aggressive ($20) and conservative ($2) target hikes could narrow further as consensus builds or fragments.
JPMorgan and Visa Show Selective Financials Strength
JPMorgan (JPM) recently appeared on both the upgrade side for DAR and for COF, suggesting its analysts are actively reassessing models across sectors this week. During the session, JPM traded at $310.29, little changed (+0.1%), reflecting a broader tendency for investors to maintain positions in large financials rather than making sector-wide rotations. Visa (V) fared modestly better, up 0.6% at $317.02. Truist previously flagged Visa as one of the card names likely to endure investor scrutiny and support, citing a peer group that also includes Capital One, Citi, Schwab, and Mastercard. The muted price action and absence of abnormal volatility or options activity across both names suggest the current market reaction is absorbable within routine analyst model adjustments.
COF’s Analyst Cuts and Brex Deal Put Focus on Execution
For Capital One (COF), the investment story is marked by a drop in its fair value estimate from $269.67 to $257.90, in line with a series of target reductions by major Wall Street firms including BofA, Barclays, Wells Fargo, TD Cowen, and others. BofA, for example, cut its target in March to $254 from $280, responding to a reset in consumer finance sector outlooks. The $5.15 billion Brex acquisition is positioned as a strategic move into business payments and spend management. Wells Fargo suggests the Brex partnership builds on Capital One’s existing card programs rather than aiming for a dramatic growth leap. JPMorgan’s recent upgrade places it in the minority among largely downwardly revised targets.
Historically, periods when card issuers balanced execution uncertainty with new fintech deals saw share prices drift until integration results came through in earnings. The current skepticism around COF’s Brex integration echoes that dynamic, with analysts and investors awaiting proof of revenue impact before a rerating.
Upcoming Catalysts: Regulatory Rollouts and Deal Integration in Focus
For Darling Ingredients (DAR), the principal variable to track is the implementation of EPA RFS guidelines, as highlighted by Jefferies. Further regulatory clarity could prompt target convergence and additional ratings action among analysts. Investors should watch for both EPA commentary and management's updates on volume and margin expectations in the coming earnings call.
For Capital One (COF), attention turns to the timeline and financial guidance related to the Brex integration. While JPMorgan's upgrade provides a potential source of optimism, broad-based skepticism remains. Whether Brex yields tangible improvements in corporate card revenue—and how it offsets ongoing macro headwinds—will likely determine if COF can reclaim higher valuation territory. The integration outcome and updated revenue commentary will be top of mind into upcoming quarters.
